Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response | GenomeWeb
NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
 
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.